Evidence map›Paper›PMID 33298175›Full record

SynthesisSystematic reviews2020

Men's willingness to pay for prostate cancer screening: a systematic review.

Hiro Farabi, Aziz Rezapour, Najmeh Moradi, Seyed Mohammad Kazem Aghamir, Jalil Koohpayehzadeh

Abstract readSystematic Review
In one paragraph

Synthesis in Systematic reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hiro FarabiDepartment of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Aziz RezapourHealth Management and Economics Research Center, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. Rezapour.a@iums.ac.ir.
Najmeh MoradiHealth Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran, Iran University of Medical Sciences, Tehran, Iran.
Seyed Mohammad Kazem AghamirUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Jalil KoohpayehzadehPreventive Medicine and Public Health Research Center, Psychosocial Health Research Institute. Community and Family Medicine Departmentm School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to review studies on willingness to pay (WTP) for prostate cancer screening.

methodsThis systematic-review was conducted based on the Preferred Reporting Items for Systematic Reviews guidelines. By searching six-health-database, WTP studies on prostate cancer screening using contingent valuation method published in English until March 2020 were included and those with unavailable full-text and inadequate quality-assessment scores were excluded. Smith checklist was used for the quality assessment. Extracted WTPs were converted to US dollar in 2018 using exchange rate parity and net present value formula to make comparison. Factors' effect was assessed by vote counting.

resultsSix final studies published after 2006 reported above 70% Smith checklist items needed to be considered in contingent valuation study reports. Seven factors have positive effects on WTP. The reported WTP value varied from 11$ to 588$ in Japan and Germany, respectively.

conclusionWTP for prostate cancer screening was positive among all studied men. The results of factors' effect assessment showed that better understanding prostate cancer risks or screening tests and factors such as age, income, family history of cancer, hospitalization history, and educational level have positive effects. Moreover, prostate-specific antigen history, health insurance, employment, and subject's health assessment received less attention. The results' generalization to all countries is not applicable because there are no studies for low- and middle-income countries. SYSTEMATIC REVIEW REGISTRATION: PROSPERO 2020 CRD42020172789.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsEarly Detection of CancerGermanyHumansInsurance, HealthMaleSurveys and QuestionnairesProstate-Specific AntigenContingent valuation methodEarly detectionProstate cancer screeningSystematic reviewWillingness to pay

Identifiers

PMID33298175
PMCPMC7727201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.